Data mining of the FDA Adverse Event Reporting System (FAERS) from 2022 to 2024 identified 2,451 adverse event reports listing dextromethorphan/bupropion (D/B) as the primary suspect. Psychiatric disorders (22.07%) and nervous system disorders (18.77%) were most common, mostly in adults aged 18–44 years. Median time to onset of adverse events was 2 days. Nearly 20 novel adverse events not in the label were detected, including sensation of inebriation and panic attacks. Risk signals for suicide/self-injury with D/B were significantly lower than with bupropion or esketamine, but still warrant attention. The authors recommend careful monitoring of psychiatric and nervous system disorders and further pharmacoepidemiological research on dissociative disorders.
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—alter levels of dopamine and serotonin and their metabolites in specific rat brain regions, including the prefrontal cortex, nucleus accumbens, dorsolateral striatum, and hippocampus. The effects vary by brain region and compound, with dopamine and serotonin systems playing key roles. These findings provide insight into the neurochemical actions of tryptamine hallucinogens.
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—showed acute toxic effects, reduced movement, and triggered head-twitch responses (a sign of hallucinogenic-like behavior) in mice. Pretreatment with a low dose of M100907, a 5-HT2A receptor antagonist, blocked the head-twitch responses caused by all three substances. The findings indicate these compounds are toxic, inhibit locomotor activity, and have hallucinogenic properties, providing experimental data to support future regulation and mechanistic research.